Anti-Therapeutic Action: mania

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial

mycolabadmin

Researchers tested whether combining psilocybin therapy with mindfulness training could better treat depression and burnout in frontline healthcare workers than mindfulness training alone. Twenty-five doctors and nurses participated in the study, with some receiving mindfulness training combined with psilocybin therapy in a group setting, while others received mindfulness training only. After two weeks, those who received the combined treatment showed significantly greater improvements in depression symptoms and burnout, with no serious side effects reported. This suggests that psilocybin-assisted therapy combined with mindfulness training could be a promising treatment for depression and burnout among healthcare professionals.

Read More »

A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics

mycolabadmin

Psychedelic compounds like psilocybin and ketamine show promise in treating serious mental health conditions including PTSD and depression. The FDA carefully evaluates these drugs through multi-phase clinical trials to ensure they are safe and effective. While California has proposed making psychedelics more widely available through legislation, the FDA’s thorough approval process provides important protections by identifying potential risks and ensuring proper medical oversight.

Read More »

A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia

mycolabadmin

Australia has recently approved psilocybin and MDMA for treating severe depression and PTSD when used with professional therapy support. This paper creates a comprehensive guide outlining all the regulatory, professional, and safety considerations needed to safely deliver these treatments in clinical settings. The researchers interviewed 11 experts and reviewed existing research to identify 102 specific matters that need clear guidelines, such as what qualifications therapists need, where treatments can be delivered, how patients should be screened, and what safety measures are essential.

Read More »
Scroll to Top